Comparison between peripheral blood progenitor cell collection on the 4 or 5 day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.
作者信息
Passeri Cecilia, Iuliani Ornella, Di Ianni Mauro, Sorrentino Carlo, Giancola Raffaella, Abbruzzese Luciano, Dallavalle Franco M, Gattillo Salvatore, Mariano Maria T, Martino Massimo, Ostuni Angelo, Savignano Chiara, Santoleri Luca, Tison Tiziana, Vacca Michele, Accorsi Patrizia
机构信息
Department of Oncology and Hematology, Ospedale Civile "Santo Spirito", ASL Pescara, Pescara, Italy.
Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
出版信息
Blood Transfus. 2023 Jan;21(1):37-41. doi: 10.2450/2022.0026-22. Epub 2022 Aug 9.
Abstract
摘要
相似文献
1
Comparison between peripheral blood progenitor cell collection on the 4 or 5 day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.异基因干细胞供者在粒细胞集落刺激因子治疗第4天或第5天进行外周血祖细胞采集的比较：对造血祖细胞单采指南的启示
Blood Transfus. 2023 Jan;21(1):37-41. doi: 10.2450/2022.0026-22. Epub 2022 Aug 9.
2
High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.高剂量与标准剂量非格司亭（重组人粒细胞集落刺激因子）用于动员异基因供者外周血祖细胞及CD34(+)免疫选择
J Clin Oncol. 1999 Jul;17(7):2160-72. doi: 10.1200/JCO.1999.17.7.2160.
4
Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.使用改良的目标值定制方法改善外周血造血祖细胞采集前CD34+细胞产量的预测
Biol Blood Marrow Transplant. 2016 Apr;22(4):763-767. doi: 10.1016/j.bbmt.2015.11.016. Epub 2015 Nov 28.
5
Forensic sequencing of Salmonella cultured from hematopoietic progenitor cell products collected by apheresis from two asymptomatic donors.对从两名无症状供体通过单采术采集的造血祖细胞产品中培养出的沙门氏菌进行法医测序。
Transfusion. 2023 Aug;63(8):1615-1617. doi: 10.1111/trf.17489.
6
Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors.大剂量粒细胞集落刺激因子方案用于健康供体外周血祖细胞动员的疗效与毒性
Bone Marrow Transplant. 1999 Dec;24(12):1273-8. doi: 10.1038/sj.bmt.1702073.
7
Analysis of apheresis content of progenitor cell collections from normal donors to whom granulocyte-colony-stimulating factor is administered.对接受粒细胞集落刺激因子的正常供者祖细胞采集物的单采成分分析。
Transfusion. 1996 Nov-Dec;36(11-12):943-7. doi: 10.1046/j.1537-2995.1996.36111297091734.x.
8
Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.使用中剂量非格司亭加大量单采术对异基因移植的干细胞单采产物进行分析。
Ann Hematol. 2001 Apr;80(4):201-8. doi: 10.1007/s002770100289.
9
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
10
Prediction of number of apheresis procedures necessary in healthy donors to attain minimally required peripheral blood CD34+ cells.预测健康供者中需要进行多少次单采术以获得最小外周血 CD34+细胞需求量。
Transfusion. 2009 Nov;49(11):2384-9. doi: 10.1111/j.1537-2995.2009.02314.x. Epub 2009 Jul 17.
引用本文的文献
1
Population Pharmacokinetic-Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34 Cell Harvesting.粒细胞集落刺激因子的群体药代动力学-药效学建模以优化CD34细胞采集的给药剂量和时间。
Clin Transl Sci. 2025 Jan;18(1):e70121. doi: 10.1111/cts.70121.
2
Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges.成人自体/异体移植中的干细胞采集和动员：关键点和未来挑战。
Cells. 2024 Mar 28;13(7):586. doi: 10.3390/cells13070586.
3
The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction.阿尔茨海默病中的 5HT2b 受体：患者大脑中水平升高，以及拮抗剂可减弱淀粉样蛋白和 tau 诱导的功能障碍。
J Alzheimers Dis. 2024;98(4):1349-1360. doi: 10.3233/JAD-240063.
本文引用的文献
1
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.采用普乐沙福对动员效果不佳的异基因造血干细胞供者进行挽救性治疗：一项前瞻性Ⅱ期试验的结果。
Bone Marrow Transplant. 2021 Mar;56(3):635-645. doi: 10.1038/s41409-020-01053-4. Epub 2020 Oct 7.
2
Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.优化干细胞动员策略以改善患者预后：指南与建议综述
Int J Hematol Oncol Stem Cell Res. 2017 Jan 1;11(1):78-88.
3
Advances in haploidentical stem cell transplantation for hematologic malignancies.单倍体相合造血干细胞移植治疗血液系统恶性肿瘤的进展
Leuk Lymphoma. 2016 Aug;57(8):1766-75. doi: 10.3109/10428194.2016.1167204. Epub 2016 Apr 13.
4
Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors.在第4天采集外周血祖细胞是可行且有效的，同时减少了健康供体接受粒细胞集落刺激因子的暴露。
Transfusion. 2015 Jun;55(6):1269-74. doi: 10.1111/trf.13002. Epub 2015 Feb 3.
5
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study.确定预测造血祖细胞成功动员的供体特征：一项意大利多中心研究的结果
Transfusion. 2014 Aug;54(8):2028-33. doi: 10.1111/trf.12612. Epub 2014 Mar 3.
6
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.无关供者骨髓与外周血造血干细胞捐献的急性毒性：来自美国骨髓捐献者项目的前瞻性试验结果。
Blood. 2013 Jan 3;121(1):197-206. doi: 10.1182/blood-2012-03-417667. Epub 2012 Oct 29.
7
A multiple regression analysis on factors influencing haematopoietic progenitor cell collection for autologous transplantation.影响自体移植造血祖细胞采集的因素的多元回归分析。
Transfus Apher Sci. 2012 Oct;47(2):223-7. doi: 10.1016/j.transci.2012.06.009. Epub 2012 Jul 21.
8
Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.保障造血干细胞捐献者的长期健康：维护捐献者安全与信任的持续且不断发展的过程。
Expert Rev Hematol. 2012 Feb;5(1):1-3. doi: 10.1586/ehm.11.78.
9
Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process.成人和儿童外周血造血祖细胞动员和采集的最佳实践：意大利细胞分离和处理协会（SIDEM）和意大利骨髓移植组（GITMO）共识过程的结果。
Transfusion. 2012 Apr;52(4):893-905. doi: 10.1111/j.1537-2995.2011.03385.x. Epub 2011 Oct 7.
10
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.非亲缘供者动员外周血造血干细胞采集的安全性和有效性：3928例供者的单中心12年经验
Blood. 2009 Oct 29;114(18):3757-63. doi: 10.1182/blood-2009-04-218651. Epub 2009 Aug 7.
Zotero 插件